Abstract
The pharmaceutical industry is facing an ever increasing challenge to deliver safer and more effective medicines. Traditionally, drug discovery programs were driven solely by potency, regardless of the properties. As a result, the development of non-drug-like molecules was costly, had high risk and low success rate. To meet the challenges, the bar has been rising higher for drug candidates. They not only need to be active, but also drug-like to be advanced to clinical development. Drug-like properties, such as solubility, permeability, metabolic stability and transporter effects are of critical importance for the success of drug candidates. They affect oral bioavailability, metabolism, clearance, toxicity, as well as in vitro pharmacology. Insoluble and impermeable compounds can result in erroneous biological data and unreliable SAR in enzyme and cell-based assays. Rapid metabolism by enzymes and high efflux by transporters can lead to high clearance, short half-life, low systemic exposure and inadequate efficacy. Early property information helps teams make informed decisions and avoids wasting precious resources. Structure-property relationships are essential to guide structural modification to improve properties. High throughput ADME/TOX assays have been implemented and are being widely used to drive drug discovery projects in parallel with activity screening. Property design has become an integrated and inseparable part of the modern drug discovery paradigm. The approach has been proven to be a winning strategy.
Keywords: ADME/TOX, solubility, permeability, metabolism, transporters, P-glycoprotein, MRP2, BCRP
Current Pharmaceutical Design
Title: Drug-Like Property Concepts in Pharmaceutical Design
Volume: 15 Issue: 19
Author(s): Li Di, Edward H. Kerns and Guy T. Carter
Affiliation:
Keywords: ADME/TOX, solubility, permeability, metabolism, transporters, P-glycoprotein, MRP2, BCRP
Abstract: The pharmaceutical industry is facing an ever increasing challenge to deliver safer and more effective medicines. Traditionally, drug discovery programs were driven solely by potency, regardless of the properties. As a result, the development of non-drug-like molecules was costly, had high risk and low success rate. To meet the challenges, the bar has been rising higher for drug candidates. They not only need to be active, but also drug-like to be advanced to clinical development. Drug-like properties, such as solubility, permeability, metabolic stability and transporter effects are of critical importance for the success of drug candidates. They affect oral bioavailability, metabolism, clearance, toxicity, as well as in vitro pharmacology. Insoluble and impermeable compounds can result in erroneous biological data and unreliable SAR in enzyme and cell-based assays. Rapid metabolism by enzymes and high efflux by transporters can lead to high clearance, short half-life, low systemic exposure and inadequate efficacy. Early property information helps teams make informed decisions and avoids wasting precious resources. Structure-property relationships are essential to guide structural modification to improve properties. High throughput ADME/TOX assays have been implemented and are being widely used to drive drug discovery projects in parallel with activity screening. Property design has become an integrated and inseparable part of the modern drug discovery paradigm. The approach has been proven to be a winning strategy.
Export Options
About this article
Cite this article as:
Di Li, Kerns H. Edward and Carter T. Guy, Drug-Like Property Concepts in Pharmaceutical Design, Current Pharmaceutical Design 2009; 15 (19) . https://dx.doi.org/10.2174/138161209788682479
DOI https://dx.doi.org/10.2174/138161209788682479 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fusion Protein Targeted Antiviral Peptides: Fragment-Based Drug Design (FBDD) Guided Rational Design of Dipeptides Against SARS-CoV-2
Current Protein & Peptide Science In Vivo and In Vitro Evaluation of the Therapeutic Potential of Some Turkish Scorzonera Species as Wound Healing Agent
Current Pharmaceutical Design Identification of Potential Inhibitors Against SARS-CoV-2 Using Computational Drug Repurposing Study
Current Bioinformatics The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents
Current Medicinal Chemistry Drug Repurposing for Cancer Therapy in the Era of Precision Medicine
Current Molecular Pharmacology Antitumor Carbazoles
Anti-Cancer Agents in Medicinal Chemistry Recent Studies on the Pharmacological Activities and Structural Modifications of Compound-K
Mini-Reviews in Medicinal Chemistry Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement
Current Molecular Pharmacology Synthesis and Antiacetylcholinesterase Activity Evaluation of New 2-aryl Benzofuran Derivatives
Letters in Drug Design & Discovery Structural Stability and High Temperature Tolerance of Bilayer Nanoribbons Composited with Graphene and Borophene#
Current Nanoscience The Role of MicroRNA-126 in Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Impact of Cerebral Oxygen Saturation Monitoring on Short-term Neurodevelopmental Outcomes in Neonates with Encephalopathy - A Prospective Cohort Study
Current Pediatric Reviews Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design The Role of Inflammatory and Cytokine Biomarkers in the Pathogenesis of Frailty Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Improving Brain MR Image Classification for Tumor Segmentation using Phase Congruency
Current Medical Imaging Protein Tyrosine Phosphatases and their Inhibitors
Current Medicinal Chemistry Synthesis, Antibacterial, and Cytotoxicity Evaluation of Oleanolic Acid-4-aminoquinoline Based Hybrid Compounds
Recent Advances in Anti-Infective Drug Discovery Long Non-coding RNA Therapeutics: Recent Advances and Challenges
Current Drug Targets P-selectin Cell Adhesion Molecule in Inflammation, Thrombosis, Cancer Growth and Metastasis
Current Medicinal Chemistry The Discovery of Novel Chemotypes of p38 Kinase Inhibitors
Current Topics in Medicinal Chemistry